Imaging DNA synthesis in vivo with18F-FMAU and PET

Journal of Nuclear Medicine

Volumn 46, Issue 2, 2005, Pages 292-296

  Sun, Haihao ^a,b   Mangner, Thomas J ^b   Collins, Jerry M ^c   Muzik, Otto ^a,b   Douglas, Kirk ^a,b   Shields, Anthony F ^a,b,d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

FMAU; PET; Proliferation

Indexed keywords

CLEVUDINE; THYMIDINE; THYMIDINE KINASE; THYMIDINE KINASE 2; TRACER; UNCLASSIFIED DRUG; 2'-FLUORO-5-METHYLARABINOSYLURACIL; DIAGNOSTIC AGENT; DNA; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; URACIL ARABINOSIDE;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOG; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RETENTION; DRUG SYNTHESIS; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGING; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TUMOR; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; DRUG SCREENING; EVALUATION; METABOLIC CLEARANCE RATE; METHODOLOGY; TISSUE DISTRIBUTION;

ANIMALS; ARABINOFURANOSYLURACIL; DNA; DOGS; DRUG EVALUATION, PRECLINICAL; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 15844429409     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Krohn KA. Evaluation of alternative approaches for imaging cellular growth. Q J Nucl Med. 2001;45:174-178.
2. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
3. Romer W, Hanauske A, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.
4. Shields A. Monitoring treatment response. In: Wahl R, ed. Principles and Practice of Positron Emission Tomography. Philadelphia, PA: Lippincott; 2002: 252-267.
5. Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160-1166.
6. 18F-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
7. Eary JF, Mankoff DA, Spence AM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res. 1999;59:615-621.
8. 11C]Thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762.
9. Wang H, Oliver P, Nan L, et al. Radiolabeled 2′-fluorodeoxyuracil- beta-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-D- arabino-furanoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol. 2002;49:419-424.
10. 18F]FIAU, as potential PET agents for imaging cellular proliferation. Nucl Med Biol 2003:215-224.
11. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol. 1995;22:783-789.
12. Fanucchi MP, Leyland-Jones B, Young CW, Burchenal JH, Watanabe KA, Fox JJ. Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D- arabinofuranosyl)-5-methyluracil (FMAU). Cancer Treat Rep. 1985;69:55-59.
13. Abbruzzese JL, Schmidt S, Raber MN, et al. Phase I trial of 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. Invest New Drugs. 1989;7:195-201.
14. Lewis W, Levine ES, Griniuviene B, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA. 1996;93:3592-3597.
15. 76Br-BFU as proliferation markers. J Nucl Med. 2002;43:1688-1698.
16. Collins JM, Klecker RW, Katki AG. Suicide prodrugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues. Clin Cancer Res. 1999;5:1976-1981.
17. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med. 1990;31:337-342.
18. Bading JR, Shahinian AH, Bathija P, Conti PS. Pharmacokinetics of the thymidine analog 2′-fluoro-5-[(14)C]-methyl-1-beta-D- arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells. Nucl Med Biol. 2000;27:361-368.
19. Shields AF. Labeled pyrimidines in PET imaging. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, eds. Positron Emission Tomography. London, U.K.: Springer-Verlag; 2003:715-724.
20. Shields A, Grierson J, Dohmen B, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
21. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350-8358.